Kura Oncology Inc. (KURA)
Symbol Info
Listed Symbol KURA
Name Kura Oncology Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-1.73
Price Info
21 Day Moving Average $16.1552
21 Day EMA $16.371260
50 Day Moving Average $18.0558
50 Day EMA $17.188890
200 Day EMA $16.805140
200 Day Moving Average 16.234650
52 Week High $21.42
52 Week Low $10.20
52 Week Change $-7.608100
Alpha 0.006365
Beta 2.5851
Standard Deviation 0.254614
R2 0.126702
Periods 48
Share Information
10 Day Average Volume 223,377
20 Day Average Volume 205,847
30 Day Average Volume 203,647
50 Day Average Volume 286,867
Outstanding Shares 45,214,920
Float Shares 44,848,906
Percent Float 99.19%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 225
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 4,491,122
Institute Holdings Percent 93.900000
Institute Sold Previous 3 Months 2,900,124
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 366,014
Price Change
7 Day Price Change $0.5000010
7 Day Percent Change 3.22%
21 Day Price Change $0.2200003
21 Day Percent Change 1.39%
30 Day Price Change $-2.0900002
30 Day Percent Change -11.53%
Month To Date Price Change $0.8500
Month To Date Percent 5.60%
90 Day Price Change $-2.49
90 Day Percent Change -13.44%
Quarter To Date $-3.66
Quarter To Date Percent -18.59%
180 Day Price Change $0.280001
180 Day Percent Change 1.78%
200 Day Price Change $0.610001
200 Day Percent Change 3.96%
Year To Date $1.990001
Year To Date Percent 14.17%
Profile
Description Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through United States.
Details
Issue Type CS
Market Cap $724,795,168
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 45,214,920
CEO Troy E. Wilson
Employees 46
Last Audit UQ
Classification
CIK 0001422143
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 3033 Science Park Road
Suite 220
San Diego, CA 92121
Website http://www.kuraoncology.com
Facisimile
Telephone +1 858 500-8800
Email robert.uhl@westwicke.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $452,344,050
Price To Sales -
Price To Free Cash -13.6
PE High Last 5 Years -
Price To Book 2.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 2.9
Financial Strength
Total Debt To Equity 0.0
Int Coverage -80.3
Current Ratio 23.5
Leverage Ratio 1.1
Quick Ratio 23.3
Long Term Debt To Capital 0.03
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -30.6
Return On Equity -33.69
Return On Capital -34.21
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
KURA
Kura Oncol..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:ca D:20190916 05:05:02